Argenx falters in effort to expand immune drug’s use

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to be ineffective at an interim checkpoint.

Abbott increases quarterly dividend for 54th consecutive year

February 2, 2026

Haya banks $65M to scour the ‘dark genome’ for new drugs

GSK walks away from pioneering Wave RNA editing drug

February 2, 2026

Source link

Argenx falters in effort to expand immune drug’s use

Abbott increases quarterly dividend for 54th consecutive year

GSK walks away from pioneering Wave RNA editing drug

The D Brief: 3 Americans killed in Syria; Ukraine peace talks; Germany on Russian sabotage; Scharre on AI in war; And a bit more.

Rwanda to Roll Out CBDC By 2026 After Consultations, Testing

Rwanda to Roll Out CBDC By 2026 After Consultations, Testing

Leave a Reply Cancel reply

RECOMMENDED NEWS

Chinese mining giants join forces with Zimbabwe on lithium mining project

Lives transformed and hope restored

A new hope for South African municipalities drowning in debt

2024 in review: Commentary – Defense One

POPULAR NEWS

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

When Will SHIB Reach $1? Here’s What ChatGPT Says

Argenx falters in effort to expand immune drug’s use

Related posts

The D Brief: 3 Americans killed in Syria; Ukraine peace talks; Germany on Russian sabotage; Scharre on AI in war; And a bit more.

Rwanda to Roll Out CBDC By 2026 After Consultations, Testing

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS